Boston Scientific (NYSE: BSX) shares are down more than 5% today after the minimally invasive medtech company said a cybersecurity incident will make it unlikely to meet previously set full-year guidance. On July 29, the company reduced its full-year sales growth outlook to 5.5%–6.5% from the previous 7%–8.5% range. (A few months before, the company […]
MassDevice Earnings Roundup
MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance
MiniMed (Nasdaq: MMED) today reported Street-beating first-quarter revenue, upping its full-year sales guidance as it notched an early European regulatory win. The Northridge, California–based diabetes tech company, spun out of Medtronic earlier this year, announced a CE mark for its next-gen, app-controlled MiniMed Flex insulin pump — well ahead of the company’s calendar 2026 year-end target. […]
Can Medtronic continue its rebound? We’ll get more answers soon
With less than a week until Medtronic (NYSE: MDT) announces its first-quarter earnings, the world’s largest medtech company has been riding rising stock and analyst upgrades. Though still not at the heights of up to $131 per share that they saw in 2021, MDT shares have been up more than 23%, to more than $92 […]
SS Innovations beats The Street on Q2 sales as it eyes U.S., EU expansion
SS Innovations (Nasdaq: SSII) second quarter results met Wall Street consensus expectations on earnings while beating revenue forecasts. In the earnings report out yesterday, the India-based robotic surgery company reported a net loss of $2.7 million, or 1¢ per share, on revenue of $13.9 million for the three months ended June 30, 2026. Losses were […]
Stereotaxis misses on Q2 revenue, cuts back 2026 guidance
Stereotaxis (NYSE: STXS) reported mixed second-quarter results, with the robotic surgery company cutting guidance for the rest of the year. The surgical robotics company, which specializes in minimally invasive endovascular interventions, reported yesterday evening a net loss of $4.5 million, or 5¢ per share, on revenue of $7.7 million for the three months ended […]
Cardinal Health nearly doubles medtech profits, fueling Q4 earnings beat
Cardinal Health (NYSE: CAH) today released Q4 results that handily beat the Wall Street consensus on profits, even as it missed on revenue. The Dublin, Ohio pharmaceutical, medtech, and healthcare distribution giant also projected an EPS range for its new fiscal year that exceeded analysts’ expectations. CAH shares were up more than 4% to $248.60 […]
ICU Medical Q2 results beat analyst expectations, driven by infusion systems
ICU Medical (Nasdaq: ICUI) reported second-quarter results that beat Wall Street expectations, upping its full-year guidance. San Clemente, California–based ICE Medical, which specializes in IV therapy, infusion pumps and closed-system drug transfer devices, reported income of $19.1 million, or 76¢ per share, on revenue of $551.7 million for the three months ended June 30, 2026. […]
Resmed Q4 beats on earnings, guides below consensus for new fiscal year
Resmed (NYSE: RMD, ASX: RMD) announced results for its fourth quarter, coming in largely in line with analyst consensus but released guidance below consensus, citing the impact of the MatrixCare divestiture. Yesterday evening, the San Diego–based maker of sleep-apnea-treating CPAPs and other respiratory devices reported profits of $383 million, or $2.64 per share, on revenue […]
Senseonics more than doubles Q2 revenue in post-Ascensia era
Senseonics (NYSE:SENS) stock is up more than 26% today after it reported what CEO Tim Goodnow described as the strongest quarter in the implantable, long-term CGM company’s history. BTIG analysts Marie Thibault, Alexandra Pang, and Sam Eiber noted that the European commercial transition from Ascensia Diabetes Care closed in June across all four markets, bringing […]
Tandem Diabetes Care seeing early benefits of new pay-as-you-go model
Tandem Diabetes Care (Nasdaq: TNDM) says U.S. sales of its insulin pumps were boosted by a scaled pay-as-you-go reimbursement model that’s been rolling out this year. According to the San Diego–based company’s second-quarter report, released after market close yesterday, the alternative reimbursement structure, available through patients’ pharmacy benefits rather than medical benefits, eliminates upfront pump […]
iRhythm to buy VitalConnect for $287.5M after Street-beating Q2
iRhythm (Nasdaq: IRTC) announced today that it will acquire wearable biosensor and ambulatory cardiac monitoring tech company VitalConnect. The news, along with Street-beating second-quarter results, sent IRTC shares up more than 2% to $130.75 apiece in after-hours trading. iRhythm (San Francisco) said the size of the acquisition is $287.5 million — $237.5 million in cash […]
